These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32708210)

  • 1. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).
    Megdanova-Chipeva VG; Lamarca A; Backen A; McNamara MG; Barriuso J; Sergieva S; Gocheva L; Mansoor W; Manoharan P; Valle JW
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
    Rodriguez-Freixinos V; Thawer A; Capdevila J; Ferone D; Singh S
    Curr Oncol Rep; 2021 May; 23(7):80. PubMed ID: 33937962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
    Pozzari M; Maisonneuve P; Spada F; Berruti A; Amoroso V; Cella CA; Laffi A; Pellicori S; Bertani E; Fazio N
    Cancer Treat Rev; 2018 Dec; 71():39-46. PubMed ID: 30352319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
    Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy for Pancreatic Neuroendocrine Tumors.
    Lavingia V; Gohel S; Sirohi B
    Indian J Surg Oncol; 2024 May; 15(Suppl 2):305-314. PubMed ID: 38817994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating hsa-miR-5096 predicts
    Bocchini M; Tazzari M; Ravaioli S; Piccinini F; Foca F; Tebaldi M; Nicolini F; Grassi I; Severi S; Calogero RA; Arigoni M; Schrader J; Mazza M; Paganelli G
    Front Oncol; 2023; 13():1136331. PubMed ID: 37287922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
    Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
    Passhak M; McNamara MG; Hubner RA; Ben-Aharon I; Valle JW
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101836. PubMed ID: 37914565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.
    Berardi R; Morgese F; Torniai M; Savini A; Partelli S; Rinaldi S; Caramanti M; Ferrini C; Falconi M; Cascinu S
    World J Gastrointest Oncol; 2016 Apr; 8(4):389-401. PubMed ID: 27096034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment strategies in advanced neuroendocrine tumours.
    Walter T; Brixi-Benmansour H; Lombard-Bohas C; Cadiot G
    Dig Liver Dis; 2012 Feb; 44(2):95-105. PubMed ID: 21983252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
    Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
    Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat neuroendocrine tumours.
    Kiesewetter B; Raderer M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
    Singhi AD; Klimstra DS
    Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
    Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
    Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
    Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
    Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.